Envista Holdings Corporation (NYSE:NVST) Given Consensus Recommendation of “Hold” by Brokerages

Shares of Envista Holdings Corporation (NYSE:NVST) have been assigned an average recommendation of “Hold” from the fifteen research firms that are presently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, nine have assigned a hold recommendation, four have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $20.9231.

A number of equities analysts have weighed in on NVST shares. Evercore ISI boosted their price target on Envista from $19.00 to $23.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 9th. Morgan Stanley lifted their target price on Envista from $16.00 to $17.00 and gave the stock an “equal weight” rating in a research note on Friday, August 1st. UBS Group increased their price target on Envista from $18.00 to $22.00 and gave the company a “neutral” rating in a research note on Tuesday, July 29th. Wells Fargo & Company raised their price target on Envista from $17.00 to $19.00 and gave the company an “equal weight” rating in a report on Friday, August 1st. Finally, Mizuho lifted their price objective on shares of Envista from $15.00 to $18.00 and gave the stock an “underperform” rating in a research report on Friday, August 1st.

Envista Stock Performance

Shares of NVST stock opened at $21.29 on Friday. The company has a fifty day moving average price of $20.44 and a two-hundred day moving average price of $18.59. Envista has a one year low of $14.22 and a one year high of $23.00. The stock has a market cap of $3.54 billion, a P/E ratio of 66.52, a P/E/G ratio of 1.11 and a beta of 0.99. The company has a debt-to-equity ratio of 0.46, a current ratio of 2.44 and a quick ratio of 2.08.

Envista (NYSE:NVST) last released its quarterly earnings data on Thursday, July 31st. The company reported $0.26 earnings per share for the quarter, topping the consensus estimate of $0.24 by $0.02. The company had revenue of $682.10 million for the quarter, compared to analyst estimates of $638.21 million. Envista had a net margin of 2.11% and a return on equity of 4.84%. Envista’s revenue for the quarter was up 7.7% compared to the same quarter last year. During the same period in the previous year, the business earned $0.11 EPS. Envista has set its FY 2025 guidance at 1.050-1.15 EPS. As a group, equities analysts predict that Envista will post 1 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of NVST. Captrust Financial Advisors raised its holdings in Envista by 38.4% in the 2nd quarter. Captrust Financial Advisors now owns 15,465 shares of the company’s stock valued at $302,000 after acquiring an additional 4,290 shares during the period. Tidal Investments LLC boosted its holdings in shares of Envista by 8.6% during the second quarter. Tidal Investments LLC now owns 40,104 shares of the company’s stock worth $784,000 after acquiring an additional 3,159 shares during the period. Man Group plc grew its position in shares of Envista by 62.1% in the second quarter. Man Group plc now owns 59,596 shares of the company’s stock valued at $1,165,000 after purchasing an additional 22,840 shares during the last quarter. HRT Financial LP bought a new position in shares of Envista during the second quarter worth approximately $1,809,000. Finally, Holocene Advisors LP bought a new position in shares of Envista during the second quarter worth approximately $43,936,000.

About Envista

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.